Increasingly, pharmaceutical and biotechnology companies are regarding the preclinical stage of drug development as the most crucial when considering where to focus their R&D investments. Ten years ago, the dream was to use automation to develop and screen millions of compounds. This approach has not entirely panned out. Now, the focus is on improving understanding […]
2013-05-13 | Strategic Directions Intl | 177 Pages